ArticleFrontiers in neurology2026
At-home feasibility trial of genital nerve stimulation to modulate neurogenic bowel dysfunction in individuals living with spinal cord injury: a protocol.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06836739 (At-Home Feasibility Trial of Genital Nerve Stimulation to Modulate Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
At-Home Feasibility Trial of Genital Nerve Stimulation to Modulate Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Introduction: Neurogenic bowel dysfunction is a consequence of almost all spinal injuries. Primary management is via conservative treatment methods with few intermediary interventions available prior to surgical management. This protocol describes a trial to determine if genital nerve stimulation (GNS) can reliably be delivered at-home for the purpose of modulating neurogenic bowel dysfunction in people living with spinal cord injury (SCI). Methods and analysis: A total of 12 participants, aged 18 years or older with any severity of a traumatic SCI (at least 6 months post-injury) at or above the neurological level of T12 with severe neurogenic bowel dysfunction will be enrolled, randomized, and perform GNS or sham stimulation 6-8 h per day for 4 weeks. Daily bowel and stimulation diaries will be filled out by participants or caregivers to provide qualitative and feasibility data. Anorectal manometry (ARM) assessments will be performed at Baseline (before stimulation), at the End of Treatment (the next day after cessation of at-home stimulation), and at the End of Study (after 2 weeks of no stimulation). ARM assessments provide quantitative data for changes in anal sphincter and rectal function due to stimulation. Self-report questionnaires will be completed at each ARM assessment regarding neurogenic bowel dysfunction and impacts of bowel function on quality of life. Discussion: Outputs from this trial will inform research and clinical practice on the preliminary neuromodulatory effects of GNS on SCI-induced neurogenic bowel dysfunction and will guide the development of a properly powered efficacy trial testing GNS as an intermediary intervention. Ethics and dissemination: The study was approved by the MetroHealth Institutional Review Board (STUDY00000717) and registered at clinicaltrials.gov prior to enrollment of participants. Dissemination of results will be through presentations at academic meetings and in the community, and peer-reviewed medical journals. Clinical trial registration: https://clinicaltrials.gov/study/NCT06836739, identifier NCT06836739.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.